Spots Global Cancer Trial Database for Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Official Title: Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance
Study ID: NCT05461430
Conditions
Interventions
Study Description
Brief Summary: The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
xCures, Oakland, California, United States
Contact Details
Name: Mark Stevens, Phd
Affiliation: Travera Inc
Role: PRINCIPAL_INVESTIGATOR
Name: Rob Kimmerling, Phd
Affiliation: Travera Inc
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
